Bempedoic Acid a Small Molecule Drug Process and Synthesis, Innovation And /Or Advantages, Development Status And /Or Regulatory Status

Volume 3 - Issue 1

Krishnasarma Pathy*

Received:July 04, 2019;   Published: July 15, 2019

DOI: 10.32474/SCSOAJ.2019.02.000154

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Bempedoic acid (ETC-1002), a small molecule drug, promotes low density lipoprotein (LDL) receptor mediated clearance of LDL-cholesterol (LDL-C) by inhibition of adenosine triphosphate citrate lyase (ACL), a mechanism complementary to those of existing lipid-modifying therapies. Bempedoic acid is a pro-drug activated specifically within the liver where it inhibits ACL, a regulatory checkpoint within the cholesterol biosynthesis pathway. By inhibiting ACL, bempedoic acid reduces cholesterol synthesis in liver cells and triggers compensatory LDL receptor upregulation. Inhibiting ACL with bempedoic acid complements other mechanisms targeted by current therapies, resulting in additional lowering of LDL-C, without leading to increases in adverse events (AEs).b In the phase III clinical trials (NCT02666664, NCT02991118) of patients with high cardiovascular risk and elevated LDL-C not adequately controlled by their current therapy, patients are given a daily dose of 180 mg bempedoic acid as an oral tablet, whilst remaining on ongoing lipid-modifying therapy. The present paper describes the process and synthesis, innovation and /or advantages, development status and /or regulatory status of Bempedoic acid.

Keywords: Cardiovascular Disease; Hyperlipidemia; ETC-1002; Low Density Lipoprotein Cholesterol; Synthesis; Statin Associated Muscle Symptoms; Statin Intolerance; Regulatory Status

Abstract| Introduction| Development Status And/or Regulatory Designations| 8-OXO-2,2,14,14-Tetramethylpentadecanedioic Acid| 8-Hydroxy-2.2.14,14-Tetramethylpentadecanedioic Acid| Only Keto Compd Described| Conclusion| References|